Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for s...
Alnylam Pharmaceuticals, Inc. (ALNY) has a valuation score of 74/100 (moderate), profitability score of 88/100 (strong), financial health score of 100/100 (strong), Piotroski F-Score of 5/9, Altman Z-Score of 4.15 (safe zone), revenue growth of +53.0% YoY.
Neutral
Analyst Consensus
Strong BuyWall Street consensus estimates — not a PMP forecast · Updated Sep 1, 2026
Analyst Recommendations37 analysts · 2026-08-01
8
21
8
Strong Buy 8Buy 21Hold 8Sell 0Strong Sell 0
Recent Market Moves
See all ALNY moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Aug 20 | After-hours | $242.49 | +5.53% | 3.69 |
| Aug 6 | Regular | $215.32 | -5.86% | -3.91 |
| Aug 6 | After-hours | $218.47 | -4.48% | -2.99 |
| Aug 5 | Regular | $226.91 | +3.61% | 2.41 |
| Aug 5 | After-hours | $229.04 | +4.58% | 3.06 |